> ## Content Index > Fetch the complete content index at: https://www.whiteroseintelligence.com/llms.txt > Use this file to discover other available public pages before exploring further. # Beate Sander - URL: https://www.whiteroseintelligence.com/beate-sander/ - Published: 1999-01-02T11:32:00.000Z - Updated: 2025-05-01T22:32:00.000Z - Author: Liam Sturgess - Tags: Profiles, #docs, #individual **Beate Sander** is a Canadian infectious disease economist based in Toronto, Ontario. She is an associate professor at the Institute of Health Policy, Management and Evaluation (IHPME) at the University of Toronto,[\[1\]](#fn1) adjunct faculty member at the York University Department of Mathematics and Statistics and a member of its LAboratory of Mathematical Parallel Systems (LAMPS),[\[2\]](#fn2)[\[3\]](#fn3) director of Population Health Economics Research (PHER) at the Toronto General Hospital Research Institute and its Toronto Health Economics and Technology Assessment Collaborative (THETA),[\[2:1\]](#fn2)[\[4\]](#fn4) a scientist at [Public Health Ontario](https://www.whiteroseintelligence.com/Public-Health-Ontario) (PHO),[\[4:1\]](#fn4) and a member of the Modeling and Economics Research (ModERN) Network of the [Canadian Immunization Research Network](https://www.whiteroseintelligence.com/Canadian-Immunization-Research-Network) (CIRN).[\[5\]](#fn5) Sander is a member of the [National Advisory Committee on Immunization](https://www.whiteroseintelligence.com/National-Advisory-Committee-on-Immunization) (NACI), where she also chairs the Economics Task Group and co-chairs the Economic Guidelines Task Group.[\[6\]](#fn6) During the declared COVID-19 pandemic, Sander was a member of the Ontario COVID-19 Science Advisory Table (OST)[\[7\]](#fn7) and a member of Pandemics & Borders.[\[8\]](#fn8) Sander is a member of the Society for Medical Decision Making (SMDM) and the editorial board of its journal, *Medical Decision Making.*[\[9\]](#fn9) She is an associate of the Canadian Centre for Health Economics (CCHE)[\[10\]](#fn10) and a member of the Canadian Lyme Disease Research Network.[\[11\]](#fn11) ## History Sander has studied at academic institutions around the world, including the University of Toronto, Australian National University, Freiberg University of Mining and Technology, and Medizinische Fachschule Chemnitz.[\[1:1\]](#fn1) Sander led a study published in April 2010 titled “The Cost-Effectiveness of Ontario’s Universal Influenza Immunization Program,” which she credits as “the first study to provide evidence that a universal program is economically attractive in jurisdictions with influenza epidemiology and health care costs broadly similar to Ontario.”[\[12\]](#fn12) In a subsequent paper published July 2010, Sander and her co-authors concluded that “Ontario’s pandemic H1N1 immunization program was cost-effective as implemented.”[\[13\]](#fn13) In 2012, Sander joined the Institute for Clinical Evaluative Sciences (ICES) as an adjunct scientist.[\[4:2\]](#fn4) Sander served as vice president of the Society for Medical Decision Making (SMDM) in 2017-2018.[\[14\]](#fn14) On April 1, 2019, Sander became the Canada Research Chair in Economics of Infectious Diseases, affiliated with the [Canadian Institutes of Health Research](https://www.whiteroseintelligence.com/Canadian-Institutes-of-Health-Research) (CIHR) and the University of Toronto.[\[15\]](#fn15) Sander reported no conflicts of interest in a July 9, 2019 disclosure for the Canadian Lyme Disease Research Network.[\[16\]](#fn16) Sander received a $248,789 grant through ICES from the Connaught Fund for 2019-2021 for a project titled, “The benefits of pneumococcal vaccination for seniors: a Centre for Vaccine Preventable Diseases interdisciplinary project on healthy aging and immunization science.”[\[4:3\]](#fn4) ### COVID-19 Sander served in several key roles during the declared COVID-19 pandemic in Canada, including as a member of the Ontario COVID-19 Science Advisory Table (OST) and the National Advisory Committee on Immunization (NACI).[\[7:1\]](#fn7)[\[6:1\]](#fn6) Sander received reimbursement to attend NACI meetings, and acknowledged this role presented a conflict of interest with her work on the OST (including regarding [COVID-19 vaccines](https://www.whiteroseintelligence.com/COVID-19-vaccine)).[\[6:2\]](#fn6) Beate received funding from the Ontario COVID-19 Rapid Research Fund as principal investigator for an “Ontario Together” study through the University Health Network titled “Ontario’s Response to COVID-19: Balancing Trade-offs and Improving Outcomes for all Ontarians.”[\[17\]](#fn17) The CIHR provided her a grant as Co-Investigator for “Scalable, Customizable, Digital Health Communication Materials to Help Canada Address the COVID-19 Pandemic” at Witteman Lab.[\[18\]](#fn18) Beate received a grant from the Canadian Cardiovascular Society's COVID-19 Challenge for Canada Initiative for a study titled “Co-Investigator Consequences of delays in cardiac procedures and surgeries due to the COVID-19 pandemic.” Additional funding came from the Heart and Stroke Foundation of Canada and ICES.[\[19\]](#fn19) Sander participated in a December 26, 2020 SMDM webinar in which she delivered a talk titled “Ensemble Modelling to Inform COVID-19 Policy Response.”[\[20\]](#fn20)[\[21\]](#fn21) She was elected president of the SMDM for 2021-2022.[\[22\]](#fn22) Sander was interviewed in December 2021 for the *Toronto Star* on the subject of the Omicron variant.[\[23\]](#fn23) ## Activities Sander's research is focused on “developing economic strategies to evaluate interventions to combat infectious and vector-borne diseases.” She and her team “are addressing challenges in the use of costing data in economic evaluations, the need for disease-specific and comprehensive simulation models, and the broader societal impact of infectious diseases and their interventions.”[\[15:1\]](#fn15) Additional areas of interest include “Economic evaluation of health care interventions with a focus on public health, decision analysis, health economics, mathematical modeling, use of laboratory, surveillance, and administrative data for economic evaluation, public health, vaccine-preventable diseases.” Sander is principal investigator of several multidisciplinary projects funded by CIHR and other funders, including an evaluation of Zika virus and COVID-19 interventions using computer simulation. The CIHR has awarded Sander the following grants:[\[1:2\]](#fn1) - 2013-2015: $45,000.00 as PI for “Assessing the health and economic burden of mycobacterial infections using laboratory and health administrative data.” - 2013-2016: $474,627.00 as PI for “Estimating longitudinal healthcare cost for infectious diseases using administrative data.” - 2014: $15,000.00 as co-PI for “The Cost-Effectiveness of Integrated [Cervical Cancer](https://www.whiteroseintelligence.com/Cervical-cancer) Prevention Strategies in Ontario.” - 2014-2015: $99,000.00 as PI for “Assessing the health and economic burden of Lyme disease using laboratory and health administrative data.” One collaborator is Samir Patel, a co-OST member and Chief of Microbiology at Public Health Ontario. - 2014-2017: $450,000.00 as PI for “The cost-effectiveness of West Nile virus intervention strategies. A computer simulation model.” - 2014-2018: $475,367.00 as co-primary investigator for “Reducing the burden of hospital-associated Clostridium Difficile infections in Canada through optimal prevention policies: A multidisciplinary individual-based modeling approach.” Sander has also received funding from the [Canadian Immunization Research Network](https://www.whiteroseintelligence.com/Canadian-Immunization-Research-Network)) (CIRN), Ontario Health, the [Public Health Agency of Canada](https://www.whiteroseintelligence.com/Public-Health-Agency-of-Canada) (PHAC) and the [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) (WHO).[\[6:3\]](#fn6)[\[24\]](#fn24) Sander received unrestricted funding to serve as a consultant to Roche for work on Tamiflu, as well as travel grants and honoraria for speaking at meetings on pandemic influenza mitigation strategies.[\[12:1\]](#fn12) She also received a $2,500.00 award from Sanofi for Communicable Disease Epidemiology.[\[1:3\]](#fn1) ### Publications - April 6, 2010: “[Economic Appraisal of Ontario's Universal Influenza Immunization Program: A Cost-Utility Analysis](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000256)” - Published in *PLoS Medicine* - Co-authored with [Allison McGeer](https://www.whiteroseintelligence.com/Allison-McGeer) and Jeff Kwong - Funded by ICES, PHAC, and the University of Toronto - July 17, 2010: “[Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience](https://www.sciencedirect.com/science/article/abs/pii/S0264410X1000993X)” - Published in *Vaccine* - Co-authored with Allison McGeer and [David Fisman](https://www.whiteroseintelligence.com/David-Fisman) - Funded by the CIHR ## External links - [Campfire Wiki](https://www.campfire.wiki/doku.php?id=beate%5Fsander) - [Google Scholar](https://scholar.google.com/citations?user=AC66-eoAAAAJ) - [LinkedIn](https://www.linkedin.com/in/beate-sander-27a1b84/) - [X](https://x.com/BeateSander) --- 1. *Beate Sander.* Institute of Health Policy, Management and Evaluation; University of Toronto. Retrieved January 20, 2022, from [↩︎](#fnref1) [↩︎](#fnref1:1) [↩︎](#fnref1:2) [↩︎](#fnref1:3) 2. *Beate Sander.* UHN Research. Retrieved March 10, 2022, from [↩︎](#fnref2) [↩︎](#fnref2:1) 3. *Members of LAMPS.* LAboratory of Mathematical Parallel Systems. Retrieved March 11, 2022, from [↩︎](#fnref3) 4. *Beate Sander - Biography.* Institute for Clinical Evaluative Sciences (ICES). Retrieved March 10, 2022, from [↩︎](#fnref4) [↩︎](#fnref4:1) [↩︎](#fnref4:2) [↩︎](#fnref4:3) 5. *Researchers.* CIRN | Canadian Immunization Research Network. Retrieved April 22, 2022, from [↩︎](#fnref5) 6. Sander, B. (2020). *Declaration of Interest.* Ontario COVID-19 Science Advisory Table. [↩︎](#fnref6) [↩︎](#fnref6:1) [↩︎](#fnref6:2) [↩︎](#fnref6:3) 7. *About Us.* Ontario COVID-19 Science Advisory Table. Retrieved March 10, 2022, from [↩︎](#fnref7) [↩︎](#fnref7:1) 8. *Beate Sander.* Pandemic & Borders. Retrieved September 11, 2024, from [↩︎](#fnref8) 9. *Editorial Board: Medical Decision Making.* SAGE Journals. Retrieved March 10, 2022, from [↩︎](#fnref9) 10. *Associates.* Canadian Centre for Health Economics - Centre Canadien En Economie de La Santé. Retrieved March 10, 2022, from [↩︎](#fnref10) 11. *Meet The Team.* Canadian Lyme Disease Research Network. Retrieved November 26, 2021, from [↩︎](#fnref11) 12. Sander, B., Kwong, J. C., Bauch, C. T., Maetzel, A., McGeer, A., Raboud, J. M., & Krahn, M. (2010). Economic Appraisal of Ontario’s Universal Influenza Immunization Program: A Cost-Utility Analysis. *PLoS Medicine, 7*(4), e1000256\. [↩︎](#fnref12) [↩︎](#fnref12:1) 13. Sander, B., Bauch, C. T., Fisman, D., Fowler, R. A., Kwong, J. C., Maetzel, A., McGeer, A., Raboud, J., Scales, D. C., Gojovic, M. Z., & Krahn, M. (2010). Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience. *Vaccine, 28*(38), 6210–6220\. [↩︎](#fnref13) 14. *Introducing the SMDM 2017 - 2018 Officers and Trustees.* Society for Medical Decision Making. Retrieved March 10, 2022, from [↩︎](#fnref14) 15. *Beate Sander.* (2021, June 25). Canada Research Chairs. [↩︎](#fnref15) [↩︎](#fnref15:1) 16. Sander, B. (2019). *Disclosure of Conflict of Interest Definitions.* Canadian Lyme Disease Research Network. [↩︎](#fnref16) 17. *Ontario COVID-19 Rapid Research Fund.* Government of Ontario. Retrieved March 10, 2022, from [↩︎](#fnref17) 18. Parent, E. *Scalable, Customizable, Digital Health Communication Materials to Help Canada Address the COVID19 Pandemic.* Witteman Lab. Retrieved March 10, 2022, from [↩︎](#fnref18) 19. Tam, D. Y., Qiu, F., Manoragavan, R., Fremes, S. E., Hassan, A., Ko, D. T., Lauck, S. B., Naimark, D., Ouzounian, M., Sander, B., Sun, L., & Wijeysundera, H. C. (2021). The Impact of the COVID-19 Pandemic on Cardiac Procedure Wait List Mortality in Ontario, Canada. *Canadian Journal of Cardiology, 37*(10), 1547–1554\. [↩︎](#fnref19) 20. Society For Medical Decision Making. (2020, December 6). *Lessons to Serve a Growing Purpose of Economic Evaluation in the U.S. in the 2020s.* YouTube. [↩︎](#fnref20) 21. *Distance Learning Educational Events.* Society for Medical Decision Making. Retrieved March 10, 2022, from [↩︎](#fnref21) 22. *SMDM 2021 - 22 Officers & Trustees Election Results.* Society for Medical Decision Making. Retrieved March 10, 2022, from [↩︎](#fnref22) 23. Arthur, B. (2021, December 10). *Opinion | It’s hard to look this in the eye. But COVID’s worst is coming.* The Toronto Star. [↩︎](#fnref23) 24. Sander, B. (2021). *Declaration of Interest.* Ontario COVID-19 Science Advisory Table. [↩︎](#fnref24)